Prospective evaluation of genomics-guided off-label treatment

A study published in Nature evaluated 37 approved cancer drugs on 1,610 patients using the Drug Rediscovery Protocol, revealing modest overall efficacy but potential benefits for specific subgroups with targeted biomarker selection. The findings suggest off-label drug use could be valuable when combined with rigorous biomarker criteria.